Effect of magnesium sulfate on the haloperidol-induced QT prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential

Japanese Circulation Journal

Volumn 64, Issue 6, 2000, Pages 445-451

  Satoh, Yoshioki ^a   Sugiyama, Atsushi ^a   Tamura, Kohji ^a   Hashimoto, Keitaro ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Effective refractory period; Haloperidol; Long QT syndrome; Magnesium sulfate; Monophasic action potential

Indexed keywords

HALOPERIDOL; MAGNESIUM SULFATE;

ACTION POTENTIAL; ANIMAL MODEL; ARTICLE; ATRIOVENTRICULAR CONDUCTION; CONTROLLED STUDY; HEART CONDUCTION; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE POTENTIAL; HEART OUTPUT; HEART PRELOAD; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE CONDUCTION; LONG QT SYNDROME; MEAN ARTERIAL PRESSURE; NONHUMAN; QT INTERVAL; REFRACTORY PERIOD;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; DOGS; DOPAMINE ANTAGONISTS; HALOPERIDOL; LONG QT SYNDROME; MAGNESIUM SULFATE; TACHYCARDIA, VENTRICULAR;

EID: 0034051301     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.64.445     Document Type: Article

References (22)

1. Roden DM, Thompson KA, Hofman BF, Woosley RL: Clinical features and basic mechanism of quinidine-induced arrhythmias. J Am Coll Cardiol 1986; 8: 73A-78A
2. Sugiyama A, Aye NN, Katahira S, Saitoh M, Hagihara A, Matsubara Y, et al: Effects of nonsedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring. Toxicol Appl Pharmacol 1997; 143: 89-95
3. Sugiyama A, Hashimoto K: Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring. Toxicol Appl Pharmacol 1998; 152: 261-269
4. Wong CB, Windle J: Erythromycin induced torsades de pointes. Nebraska Med J 1995; 80: 285-286
5. Sharma ND, Rosman HS, Padhi ID, Tisdale JE: Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81: 238-240
6. Stratmann HG, Kennedy HL: Torsades-de-pointes associated with drugs and toxins: recognition and management. Am Heart J 1987; 113: 1470-1482
7. Kerin NZ, Somberg J: Proarrhythmia: Definition, risk factors, causes, treatment, and controversies. Am Heart J 1994; 128: 575-585
8. Volders PGA, Kulcsár A, Vos MA, Sipido KR, Wellens HJJ, Lazzara R, et al: Similarities between early and delayed afterdepolarizations induced by isoproterenol in canine ventricular myocytes. Cardiovasc Res 1997; 34: 348-359
9. Tzivoni D, Banai S, Schuger C, Benhorin J, Keren A, Gottlieb S, et al: Treatment of torsades de pointes with magnesium sulfate. Circulation 1988; 77: 392-397
10. Davidenko JM, Cohen L, Googrow R, Antzelevitch C: Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers: Effects of stimulation rate, potassium, and magnesium. Circulation 1989; 79: 674-686
11. Patterson E, Szabo B, Scherlag BJ, Lazzara R: Early and delayed after depolarizations associated with Cesium chloride-induced arrhythmias in the dog. J Cardiovasc Pharmacol 1990; 15: 323-331
12. Suessbrich H, Schuönherr R, Heinemann SH, Attari B, Lang F, Busch AE: The inhibitory effects of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 1997; 120: 968-974
13. Lawrence KR, Nasraway SA: Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of literature. Pharmacotherapy 1997; 17: 531-537
14. Sugiyama A, Aye NN, Katahira S, Hagihara A, Hashimoto K: Effects of magnesium sulfate on the canine cardiovascular system complicating astemizole overdose. J Cardiovasc Pharmacol 1997; 29: 795-800
15. Franz MR: Bridging the gap between basic and clinical electrophysiology: What can be learned from monophasic action potential recordings? J Cardiovasc Electrophysiol 1994; 5: 699-710
16. Kirchhof PF, Fabritz CL, Franz MR: Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects. Circulation 1998; 97: 2567-2574
17. Arlock P, Gullberg B, Olsson SR: Cardiac electrophysiology of four neuroleptics: melperone, haloperidol, thioridazine and chlorpromazine. Naunyn-Schmiedebergs Arch Pharmacol 1978; 304: 27-36
18. Miller DD, Hershey LA, Duffy JP, Greenblatt DJ: Serum haloperidol concentrations and clinical response in acute psychosis. J Clin Psychopharmacol 1984; 4: 305-310
19. Sugiyama A, Xue YX, Hagihara A, Saitoh M, Hashimoto K: Characterization of magnesium sulfate as an antiarrhythmic agent. J Cardiovasc Pharmacol Ther 1996; 1: 243-254
20. Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, et al: Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: A statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1999; 99: 979-982
21. Po SS, Wang DW, Yang ICH, Johnson JP Jr, Nie L, Bennett PB: Modulation of HERG potassium channels by extracellular magnesium and quinidine. J Cardiovasc Pharmacol 1999; 33: 181-185
22. ++ in rat phaeochromocytoma cells. J Physiol 1996; 466: 683-706